Best of the Blog: PharmExec's 10 Most Read Stories in 2013
Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you missed them:
Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you missed them:
1. The List So Far: FDA Breakthrough Designations 2.Ever Bullish, Al Mann Says Afrezza is Coming in 2014 3. Teva Joins Top 20: Face of Big Pharma Changes 4. Gov’t Shutdown Halts FDA Product Submissions 5.Market Access is Dead: Patien Access is the New 6. Rx Brand Managers: Will Your Products Be Covered 7. The Sunshine Act Makes for Gloomy Sales Reps 8. The Patent Black Label: Six Side Effects o India 9. The Yin and Yang of the Court Decision on 10. How to Win in the Diabetes Space 11. Ibrutinib’s Breakthrough to Market 12. The Curious Case of AstraZeneca v. ACE 13. The Rx Industry, PBMs and Obamacare 14. What Key Opinion Leaders Really Want from Pharma 15. The African Markets Pharma Can’t Ignore
1. The List So Far: FDA Breakthrough Designations
2.Ever Bullish, Al Mann Says Afrezza is Coming in Mid-April
3. Teva Joins Top 10: ‘Face’ of Big Pharma Changing
4. Gov’t Shutdown Halts FDA Product Submissions and Other Functions
5. Market Access is Dead: Patient Access is the New Prescription for Health
6. Rx Brand Managers: Will Your Products Be Covered Under Obamacare?
7. The Sunshine Act Makes for Gloomy Sales Reps
8. The Patent Black Label: Six Side Effects of India’s Novartis Glivec Ruling
9. The Yin and Yang of the Court Decision on HCR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
